Skip to main content

Novel Rx

      RT @lupuscyclopedia: #ACR2021 Dr. L Sammaritano shows evidence for using belimumab during breastfeeding @RheumNow https:
      3 years 1 month ago
      #ACR2021 Dr. L Sammaritano shows evidence for using belimumab during breastfeeding @RheumNow https://t.co/kDXXauoOZQ
      RT @doctorRBC: IL-22 as a potential biomarker of AxSpA from non-inflammatory mimickers?

      ⬆️IL-22 in AxSpA vs. contro
      3 years 1 month ago
      IL-22 as a potential biomarker of AxSpA from non-inflammatory mimickers? ⬆️IL-22 in AxSpA vs. controls ⭐️IL-22 did not correlate w/ mSASSS, BASADI, ASDAS, CRP Abs#385 #ACR21 @RheumNow https://t.co/hNtStAluJH
      RT @synovialjoints: Biologic dose tapering in #axialspondyloarthritis in 52% of patients if criteria are met (BASDAI)&lt
      3 years 1 month ago
      Biologic dose tapering in #axialspondyloarthritis in 52% of patients if criteria are met (BASDAI)< 40, physician global score< 40 and no signs of disease activity the previous year, escalation to previous dose if there is a flare @RheumNow #ACR21 Abst#0364 https://t.co/4GntJ6jS11
      RT @KDAO2011: KEEPsAKE trial 1 (DMARD-IR) and 2 (DMARD/biologic-IR) on risankizumab (IL23i) for PsA:
      👉phase 3 DBRPCT
      3 years 1 month ago
      KEEPsAKE trial 1 (DMARD-IR) and 2 (DMARD/biologic-IR) on risankizumab (IL23i) for PsA: 👉phase 3 DBRPCT 24 weeks 👉150 mg week 0,4, 16 weeks 👉improved ACR20,ACR50,ACR70 👉improved PASI90 👉improved HAQ-DI 👉no increased safety signals #ACR21 Abstr#0438 #Plenary @rheumnow https://t.co/ioIBXgV4Hi
      RT @synovialjoints: Prevention study using Abatacept in 100 patients with arthralgia is superior (61%) to placebo (31%)
      3 years 1 month ago
      Prevention study using Abatacept in 100 patients with arthralgia is superior (61%) to placebo (31%) in improving subclinical inflammation in RA at-risk patients (ACPA+, MRI+, Arthralgia+) at 6 months. No new safety issue emerged @RheumNow #ACR21 Abst#0455 https://t.co/DoRItcHfBE
      RT @Janetbirdope: #ClinicalPearl What lasts longer/⬆️retention in sero+ RA: Abatacept or TNFi or JAKi? #ACR21 abst#
      3 years 1 month ago
      #ClinicalPearl What lasts longer/⬆️retention in sero+ RA: Abatacept or TNFi or JAKi? #ACR21 abst#0463 @RheumNow Adjusting for confounding incl line of Rx / past bio Rx, #abatacept wins. But data not stratified for bio naive or exposed. Not sure if that would alter results https://t.co/1dEQncwPQF
      RT @KDAO2011: Retrospective study of FAERS database: 186 irAE w/rheum manifestation
      👉4.7% of all AEs
      👉Arthritis, m
      3 years 1 month ago
      Retrospective study of FAERS database: 186 irAE w/rheum manifestation 👉4.7% of all AEs 👉Arthritis, myositis, Sjogren, sarcoidosis were frequent 👉myositis assc w/ durvalumab, avelumab, atezolimumab and cemiplimab #ACR21 Abstr#0438 #Plenary @rheumnow https://t.co/t8UQWQicFc https://t.co/FGo6WCDQTp
      RT @drdavidliew: How can we tell whether a patient already on rituximab will have an immunogenic response to Pfizer COVI
      3 years 1 month ago
      How can we tell whether a patient already on rituximab will have an immunogenic response to Pfizer COVID-19 vaccination? Better chance of response if: - RA or SLE, not AAV or IIM - high serum IgG pre-last RTX - longer time since last RTX Israeli data #ACR21 ABST0437 @RheumNow https://t.co/yyuFd0eDH6
      ×